Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma
暂无分享,去创建一个
Wei-Hwa Lee | O. Bamodu | J. Ong | C. Yeh | Hang-Lung Chang | J. Tsai | Hang-Lung Chang | Hang-Lung Chang
[1] Haitao Zhao,et al. Alterations in DNA Damage Repair Genes in Primary Liver Cancer , 2019, Clinical Cancer Research.
[2] G. Moreno-Bueno,et al. Contribution of Epithelial Plasticity to Therapy Resistance , 2019, Journal of clinical medicine.
[3] U. Neumann,et al. Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach , 2019, International journal of molecular sciences.
[4] Shanshan Wang,et al. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies , 2018, Therapeutic advances in medical oncology.
[5] M. Korc,et al. Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells , 2018, Cell Death & Disease.
[6] S. Zhang,et al. LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. , 2018, Cancer letters.
[7] V. Jendrossek,et al. New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response , 2018, Cancers.
[8] Alan D. Lopez,et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.
[9] M. Falasca,et al. Targeting PDK1 for Chemosensitization of Cancer Cells , 2017, Cancers.
[10] D. Melisi,et al. EMT and Treatment Resistance in Pancreatic Cancer , 2017, Cancers.
[11] Greg M. Findlay,et al. Protein Kinases in Pluripotency-Beyond the Usual Suspects. , 2017, Journal of molecular biology.
[12] Alberto Puliafito,et al. PDK1: At the crossroad of cancer signaling pathways. , 2017, Seminars in cancer biology.
[13] R. Weinberg,et al. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.
[14] A. Puliafito,et al. Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination , 2017, Cancers.
[15] K. Freier,et al. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma , 2015, Expert opinion on therapeutic targets.
[16] M. Wirth,et al. Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. , 2015, Cancer research.
[17] A. Zygogianni,et al. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. , 2015, World journal of hepatology.
[18] M. Kastan,et al. The DNA damage response: implications for tumor responses to radiation and chemotherapy. , 2015, Annual review of medicine.
[19] C. Frenette,et al. Current management of hepatocellular carcinoma. , 2014, Gastroenterology & hepatology.
[20] M. Lomax,et al. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[21] Yong Li,et al. Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance , 2013, Cell Death and Disease.
[22] L. Dawson,et al. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. , 2013, International journal of radiation oncology, biology, physics.
[23] Qiang Yu,et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. , 2013, Cancer discovery.
[24] Z. Gong,et al. Inducible and repressable oncogene-addicted hepatocellular carcinoma in Tet-on xmrk transgenic zebrafish. , 2012, Journal of hepatology.
[25] M. Falasca,et al. Targeting PDK1 in cancer. , 2011, Current medicinal chemistry.
[26] J. Llovet,et al. Targeted therapies for hepatocellular carcinoma. , 2011, Gastroenterology.
[27] D. Jain,et al. Molecular Pathology of Hepatic Neoplasms: Classification and Clinical Significance , 2011, Pathology research international.
[28] S. Knapp,et al. The (un)targeted cancer kinome. , 2010, Nature chemical biology.
[29] O. Hammarsten,et al. DNA-dependent Protein Kinase-mediated Phosphorylation of Protein Kinase B Requires a Specific Recognition Sequence in the C-terminal Hydrophobic Motif* , 2009, Journal of Biological Chemistry.
[30] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[31] A. Joe,et al. Oncogene addiction. , 2008, Cancer research.
[32] J. Haveman,et al. Clonogenic assay of cells in vitro , 2006, Nature Protocols.
[33] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[34] J. Higginson. International Agency for Research on Cancer. , 1968, WHO chronicle.